Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market Regentis' GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis' preparation for commercial scale-up as clinical and regulatory milestones approach Knee cartilage damage remains one of the most…
